Oncogene - Table of Contents alert Volume 34 Issue 41

If you are unable to see the message below, click here to view.

Advertisement Validated ChIP antibodies you can TRUST – and try a sample! Partnering with epigenetics experts in the BLUEPRINT epigenome consortium, Diagenode has developed completely validated epigenetics antibodies with:   •  The highest specificity and sensitivity available  •  Unparalleled MeDIP, ChIP, and ChIP-seq results  •  Validated, so you have complete confidence in your results Learn more and try a sample today. TABLE OF CONTENTS Volume 34, Issue 41 (October 2015) In this issue Review Original Articles Short Communications Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Introducing THE DARWIN CANCER BLOG — "keeping an evolutionary eye on cancer" led by Prof. Mel Greaves and brought to you by BJC. This blog provides a forum for discussing how an evolutionary perspective is changing thinking about cancer and aims to encourage discussion and debate among specialists and general interest readers. »Start reading the latest content   Review Top Pediatric solid tumor genomics and developmental pliancy OPEN X Chen, A Pappo and M A Dyer Oncogene 2015 34: 5207-5215; advance online publication, February 2, 2015; 10.1038/onc.2014.474 Abstract | Full Text Original Articles Top Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation J Kaur and K Tikoo Oncogene 2015 34: 5216-5228; advance online publication, February 2, 2015; 10.1038/onc.2014.447 Abstract | Full Text Mitochondrial SOD2 regulates epithelial–mesenchymal transition and cell populations defined by differential CD44 expression H Kinugasa, K A Whelan, K Tanaka, M Natsuizaka, A Long, A Guo, S Chang, S Kagawa, S Srinivasan, M Guha, K Yamamoto, D K St Clair, N G Avadhani, J A Diehl and H Nakagawa Oncogene 2015 34: 5229-5239; advance online publication, February 9, 2015; 10.1038/onc.2014.449 Abstract | Full Text The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma F Amoroso, M Capece, A Rotondo, D Cangelosi, M Ferracin, A Franceschini, L Raffaghello, V Pistoia, L Varesio and E Adinolfi Oncogene 2015 34: 5240-5251; advance online publication, January 26, 2015; 10.1038/onc.2014.444 Abstract | Full Text SHP-1 is a negative regulator of epithelial–mesenchymal transition in hepatocellular carcinoma L-C Fan, C-W Shiau, W-T Tai, M-H Hung, P-Y Chu, F-S Hsieh, H Lin, H-C Yu and K-F Chen Oncogene 2015 34: 5252-5263; advance online publication, January 26, 2015; 10.1038/onc.2014.445 Abstract | Full Text HMG20A is required for SNAI1-mediated epithelial to mesenchymal transition S Rivero, M Ceballos-Chávez, S S Bhattacharya and J C Reyes Oncogene 2015 34: 5264-5276; advance online publication, February 2, 2015; 10.1038/onc.2014.446 Abstract | Full Text EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications S A Greenall, J F Donoghue, M Van Sinderen, V Dubljevic, S Budiman, M Devlin, I Street, T E Adams and T G Johns Oncogene 2015 34: 5277-5287; advance online publication, February 9, 2015; 10.1038/onc.2014.448 Abstract | Full Text Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum A Ruiz-Saenz, M Sandhu, Y Carrasco, R L Maglathlin, J Taunton and M M Moasser Oncogene 2015 34: 5288-5294; advance online publication, January 26, 2015; 10.1038/onc.2014.455 Abstract | Full Text Short Communications Top C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy S R Klein, S Piya, Z Lu, Y Xia, M M Alonso, E J White, J Wei, C Gomez-Manzano, H Jiang and J Fueyo Oncogene 2015 34: 5295-5301; advance online publication, January 26, 2015; 10.1038/onc.2014.452 Abstract | Full Text Diverse roles of STING-dependent signaling on the development of cancer J Ahn, H Konno and G N Barber Oncogene 2015 34: 5302-5308; advance online publication, February 2, 2015; 10.1038/onc.2014.457 Abstract | Full Text Advertisement Oncogenesis is an online-only, open access journal exploring the molecular basis of cancer and related phenomena. The journal seeks to promote diverse and integrated areas of molecular biology, cell biology, oncology, and genetics. The journal has an Impact Factor of 3.952. Explore the benefits of submitting your next research article: http://bit.ly/1vUuaXe Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.